Physician profile
Sayed A Tabatabai
NPI 1265552145
$6,974.40
in general payments reported to CMS, 2019-2025
32 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $262 · 2021: $347 · 2022: $1,099 · 2023: $1,599 · 2024: $1,716 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,548 · Education: $17.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,548.32 |
| Education | $17.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $991.37 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $892.20 | 2020-2024 | Acthar, Terlivaz |
| Aurinia Pharma U.S., INC. | $657.73 | 2022-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $602.94 | 2019-2025 | Jynarque |
| Mallinckrodt Enterprises LLC | $454.45 | 2019 | |
| Vifor Pharma, INC. | $427.77 | 2019-2025 | Veltassa, Korsuva |
| Horizon Therapeutics Plc | $322.50 | 2019-2023 | Krystexxa |
| Inspire Medical Systems, INC. | $295.06 | 2025 | Inspire |
| Amgen INC. | $289.68 | 2019-2025 | Tavneos, Krystexxa |
| Novartis Pharmaceuticals Corporation | $272.50 | 2023-2025 | |
| Travere Therapeutics, INC. | $255.37 | 2019-2025 | Thiola |
| Calliditas Therapeutics US INC. | $216.68 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $195.09 | 2020-2025 | Benlysta, Jesduvroq |
| Fresenius USA Marketing, INC. | $163.01 | 2023-2024 | Velphoro |
| Cormedix INC. | $157.61 | 2024-2025 | Defencath, Defencath |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.28 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $119.51 | 2024-2025 | |
| Ardelyx, INC. | $111.59 | 2023-2025 | Ibsrela |
| Kyowa Kirin, INC. | $54.53 | 2024-2025 | Crysvita |
| Amicus Therapeutics, INC. | $53.60 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $50.61 | 2023 | Soliris, Ultomiris |
| Daiichi Sankyo INC. | $47.44 | 2019-2023 | Injectafer |
| Xeris Pharmaceuticals, INC. | $46.91 | 2024 | Keveyis |
| Opko Pharmaceuticals, LLC | $29.70 | 2021-2024 | Rayaldee |
| Actelion Pharmaceuticals US, INC. | $28.67 | 2025 | Uptravi, Opsumit |
| Akebia Therapeutics INC | $27.23 | 2024 | Vafseo |
| Pharmacosmos Therapeutics INC. | $24.74 | 2023 | Monoferric |
| Janssen Pharmaceuticals, INC | $23.99 | 2024 | Xarelto |
| Scpharmaceuticals INC. | $23.24 | 2025 | |
| Hikma Pharmaceuticals USA | $16.40 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayed Tabatabai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.